Tislelizumab Approved as Second-Line Treatment for Advanced, Metastatic Esophageal Cancer
Officials Provide Update on Phase 3 CheckMate-73L Trial in NSCLC
Bemarituzumab Plus mFOLFOX6 Improves PFS, OS Rates in Gastric Cancers